GHRP-2 calculators

This hub gathers the four GHRP-2 calculators in one place — reconstitution, dose, mg ↔ units, and vial duration — pre-filled with a 5 mg / 2 mL example so the math is concrete the moment the page loads. GHRP-2 sits in the GH Secretagogue category, and the numbers each tool surfaces are tuned to how people actually log this peptide: a daily shot at the 0.1 mcg example dose. A second-generation GH secretagogue with a selectivity profile between GHRP-6 and ipamorelin.

At the example concentration of 2.5 mg/mL, a 0.1 mcg GHRP-2 dose draws roughly 4 units on a U-100 insulin syringe — the Dose calculator on the hub shows that working in real time, and the mg ↔ units converter flips it back the other way for people who think in milligrams. The Reconstitution calculator answers the day-one question (how much bacteriostatic water to add and what concentration that gives), and the Vial Duration calculator answers the planning question (how many weeks one vial covers).

For this 5 mg GHRP-2 vial, the example numbers imply about 50 doses per vial and roughly 7.1 weeks of coverage at 7 doses per week — that's the math the Vial Duration tool exposes, and it's the number most people use to decide when to reorder. Every calculator on the hub uses these same five inputs (vial mg, diluent mL, dose, doses-per-week, syringe type), so changing your real numbers in one tool gives consistent answers across the others.

Published research on GHRP-2 frequently documents protocols that involve multiple administrations throughout the day, typically ranging from one to three separate doses. This dosing cadence is a direct consequence of the peptide's short half-life, a common characteristic among all synthetic ghrelin agonists that necessitates repeated stimulus to study sustained effects. A standard U-100 insulin syringe is almost universally employed for this purpose, as it provides the necessary precision to accurately measure and draw the small liquid volumes corresponding to typical dose magnitudes of around 100 micrograms.

The timing of administration is a critical variable studied in these protocols, with doses often scheduled on an empty stomach, such as upon waking or several hours after a meal. This timing is planned to prevent the potential blunting effect that circulating glucose and fatty acids can have on the pulsatile release of growth hormone. For anyone documenting a personal protocol, this makes time-stamping each log entry essential. Without this data point, a log of a three-times-daily schedule rapidly degrades into a simple tally that cannot be used to analyze patterns or correlate observed outcomes to a specific morning, mid-day, or evening administration.

A second consideration documented in the comparative literature is how a multi-dose schedule interacts with cumulative weekly exposure. Three 100 mcg doses per day for seven days produce 2,100 mcg of weekly exposure from a single 5 mg vial, which means a vial reconstituted at the example concentration of 2,500 mcg/mL lasts roughly two and a half weeks at that cadence — a useful number to know in advance when planning reorders, since running out mid-cycle disrupts whatever pattern the log was attempting to capture. Researchers who document this kind of long-running protocol typically also note ambient temperature during transport between dose times, because a vial carried in a warm bag for several hours each day is not in the same storage condition as one that lives continuously in a refrigerator, and the difference is worth recording even if the visible appearance of the solution does not change.